• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (46)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid -Amyloid 42 in Adults With Normal Cognition

Elaine R. Peskind, MD; Ge Li, PhD, MD; Jane Shofer, MS; Joseph F. Quinn, MD; Jeffrey A. Kaye, MD; Chris M. Clark, MD; Martin R. Farlow, MD; Charles DeCarli, MD; Murray A. Raskind, MD; Gerard D. Schellenberg, PhD; Virginia M.-Y. Lee, PhD; Douglas R. Galasko, MD

Arch Neurol. 2006;63:936-939.

Background  Decreased cerebrospinal fluid (CSF) -amyloid 42 (A₄₂) concentration, but not A₄₀ concentration, is a biomarker for Alzheimer disease. This A₄₂ concentration decrease in CSF likely reflects precipitation of A₄₂ in amyloid plaques in brain parenchyma. This pathogenic plaque deposition begins years before the clinical expression of dementia in Alzheimer disease. Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease.

Objective  To estimate the interactive effects of normal aging and presence of the APOE*4 allele on CSF A₄₂ concentration in adults with normal cognition across the life span.

Design  The CSF was collected in the morning after an overnight fast using Sprotte 24-g atraumatic spinal needles. The CSF A₄₂ and A₄₀ concentrations were measured in the 10th milliliter of CSF collected by sandwich enzyme-linked immunosorbent assay. The APOE genotype was determined by a restriction digest method.

Subjects  One hundred eighty-four community volunteers with normal cognition aged 21 to 88 years.

Results  The CSF A₄₂, but not the A₄₀, concentration decreased significantly with age. There was a sharp decrease in CSF A₄₂ concentration beginning in the sixth decade in subjects with the APOE*4 allele. This age-associated decrease in CSF A₄₂ concentration was significantly and substantially greater in subjects with the APOE*4 allele compared with those without the APOE*4 allele.

Conclusion  These CSF A₄₂ findings are consistent with acceleration by the APOE*4 allele of pathogenic A₄₂ brain deposition starting in later middle age in persons with normal cognition.

Author Affiliations: VA Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center (Drs Peskind, Li, and Raskind and Ms Shofer), Geriatric Research, Education, and Clinical Center (Dr Schellenberg), and Departments of Psychiatry and Behavioral Sciences (Drs Peskind, Li, and Raskind) and Medicine (Dr Schellenberg), University of Washington School of Medicine, Seattle; Department of Neurology, Oregon Health and Science University (Drs Quinn and Kaye) and Portland VA Medical Center (Dr Quinn), Portland; Department of Neurology, Institute on Aging, University of Pennsylvania, Philadelphia (Drs Clark and Lee); Department of Neurology, Indiana University School of Medicine, Indianapolis (Dr Farlow); Department of Neurology, University of California at Davis, Sacramento (Dr DeCarli); Department of Neurosciences, University of California at San Diego and VA Medical Center, San Diego (Dr Galasko).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Time Will Be of the Essence in Treating Alzheimer Disease
Roger N. Rosenberg
JAMA. 2006;296(3):327-329.
EXTRACT | FULL TEXT  

Treating Alzheimer Disease: Time Matters
Roger N. Rosenberg
Arch Neurol. 2006;63(7):926-928.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

APOE modifies the association between A{beta} load and cognition in cognitively normal older adults
Kantarci et al.
Neurology 2012;78:232-240.
ABSTRACT | FULL TEXT  

Evidence for Ordering of Alzheimer Disease Biomarkers
Jack et al.
Arch Neurol 2011;68:1526-1535.
ABSTRACT | FULL TEXT  

ABCB1 Genotype and CSF {beta}-Amyloid in Alzheimer Disease
Kohen et al.
J Geriatr Psychiatry Neurol 2011;24:63-66.
ABSTRACT  

Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment
Bayer-Carter et al.
Arch Neurol 2011;68:743-752.
ABSTRACT | FULL TEXT  

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
Jack et al.
Brain 2010;133:3336-3348.
ABSTRACT | FULL TEXT  

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer et al.
Arch Neurol 2010;67:949-956.
ABSTRACT | FULL TEXT  

Preclinical Evidence of Alzheimer Changes: Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings
Petrie et al.
Arch Neurol 2009;66:632-637.
ABSTRACT | FULL TEXT  

Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles
Bennett et al.
Neurology 2009;72:1495-1503.
ABSTRACT | FULL TEXT  

Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings et al.
Neurology 2007;69:1622-1634.
ABSTRACT | FULL TEXT  

CSF tau/A{beta}42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li et al.
Neurology 2007;69:631-639.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan et al.
Arch Neurol 2007;64:343-349.
ABSTRACT | FULL TEXT  

Time Will Be of the Essence in Treating Alzheimer Disease
Rosenberg
JAMA 2006;296:327-329.
FULL TEXT  

Treating Alzheimer disease: time matters.
Rosenberg
Arch Neurol 2006;63:926-928.
FULL TEXT